- Home
- GHRS vs NRK Comparison
GHRS vs NRK Comparison
Compare GHRS & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- NRK
- Stock Information
- Founded
- GHRS 2018
- NRK 2002
- Country
- GHRS Ireland
- NRK United States
- Employees
- GHRS N/A
- NRK N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- NRK Trusts Except Educational Religious and Charitable
- Sector
- GHRS Health Care
- NRK Finance
- Exchange
- GHRS Nasdaq
- NRK Nasdaq
- Market Cap
- GHRS 868.7M
- NRK 922.1M
- IPO Year
- GHRS 2021
- NRK N/A
- Fundamental
- Price
- GHRS $9.10
- NRK $9.94
- Analyst Decision
- GHRS Strong Buy
- NRK
- Analyst Count
- GHRS 7
- NRK 0
- Target Price
- GHRS $30.86
- NRK N/A
- AVG Volume (30 Days)
- GHRS 208.9K
- NRK 187.3K
- Earning Date
- GHRS 05-02-2025
- NRK 01-01-0001
- Dividend Yield
- GHRS N/A
- NRK 4.10%
- EPS Growth
- GHRS N/A
- NRK N/A
- EPS
- GHRS N/A
- NRK N/A
- Revenue
- GHRS N/A
- NRK N/A
- Revenue This Year
- GHRS N/A
- NRK N/A
- Revenue Next Year
- GHRS N/A
- NRK N/A
- P/E Ratio
- GHRS N/A
- NRK N/A
- Revenue Growth
- GHRS N/A
- NRK N/A
- 52 Week Low
- GHRS $6.00
- NRK $8.95
- 52 Week High
- GHRS $20.50
- NRK $11.09
- Technical
- Relative Strength Index (RSI)
- GHRS 39.47
- NRK 33.86
- Support Level
- GHRS $8.51
- NRK $9.87
- Resistance Level
- GHRS $9.36
- NRK $9.97
- Average True Range (ATR)
- GHRS 0.79
- NRK 0.16
- MACD
- GHRS -0.11
- NRK -0.01
- Stochastic Oscillator
- GHRS 33.94
- NRK 44.21
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.